Vaxcyte, Inc. (PCVX)
70.99
+5.98
(+9.19%)
USD |
NASDAQ |
Oct 09, 14:56
Vaxcyte Enterprise Value : 8.042B for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 8.042B |
| October 07, 2026 | 8.323B |
| October 06, 2026 | 8.286B |
| October 05, 2026 | 9.317B |
| October 02, 2026 | 6.806B |
| October 01, 2026 | 6.744B |
| September 30, 2026 | 6.867B |
| September 29, 2026 | 6.837B |
| September 28, 2026 | 7.065B |
| September 25, 2026 | 6.767B |
| September 24, 2026 | 6.867B |
| September 23, 2026 | 6.808B |
| September 22, 2026 | 7.174B |
| September 21, 2026 | 7.159B |
| September 18, 2026 | 7.045B |
| September 17, 2026 | 7.369B |
| September 16, 2026 | 7.138B |
| September 15, 2026 | 7.201B |
| September 14, 2026 | 7.249B |
| September 11, 2026 | 7.239B |
| September 10, 2026 | 7.156B |
| September 09, 2026 | 7.245B |
| September 08, 2026 | 7.368B |
| September 04, 2026 | 7.484B |
| September 03, 2026 | 7.485B |
| Date | Value |
|---|---|
| September 02, 2026 | 7.545B |
| September 01, 2026 | 7.433B |
| August 31, 2026 | 7.423B |
| August 28, 2026 | 7.292B |
| August 27, 2026 | 7.483B |
| August 26, 2026 | 7.474B |
| August 25, 2026 | 7.474B |
| August 24, 2026 | 7.587B |
| August 21, 2026 | 7.695B |
| August 20, 2026 | 7.510B |
| August 19, 2026 | 7.794B |
| August 18, 2026 | 7.285B |
| August 17, 2026 | 7.348B |
| August 14, 2026 | 7.036B |
| August 13, 2026 | 7.151B |
| August 12, 2026 | 7.265B |
| August 11, 2026 | 7.203B |
| August 10, 2026 | 7.068B |
| August 07, 2026 | 7.036B |
| August 06, 2026 | 7.155B |
| August 05, 2026 | 6.725B |
| August 04, 2026 | 6.547B |
| August 03, 2026 | 6.379B |
| July 31, 2026 | 6.459B |
| July 30, 2026 | 6.731B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 74.75B |
| Arrowhead Pharmaceuticals, Inc. | 8.347B |
| Oncolytics Biotech, Inc. | 64.19M |
| Sangamo Therapeutics, Inc. | 49.79M |
| Sarepta Therapeutics, Inc. | 2.181B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -284.30M |
| Total Expenses (Quarterly) | 284.30M |
| EPS Diluted (Quarterly) | -1.968 |
| Earnings Yield | -10.86% |
| Normalized Earnings Yield | -10.86 |